Nasal vaccination of six squirrel monkeys (Saimiri sciureus): Improved immunization protocol against Toxoplasma gondii with a nanoparticle-born vaccine

Fasquelle, François; Scuotto, Angelo; Vreulx, Anaïs-Camille; Petit, Thierry; Charpentier, Thomas; Betbeder, Didier

doi:10.1016/j.ijppaw.2023.09.002

Cited by 3 publications

(2 citation statements)

References 20 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The work herein provides part of the foundation for such studies. The ICT has also been utilized in studies of seroprevalence in wild-life and in characterizing epidemics taking place in zoos in primates and marsupials [ 53 , 54 ]. These latter studies are being performed in conjunction with studies of a new vaccine for zoo animals.…”

Section: Discussion (With S1 Commentary )mentioning

confidence: 99%

Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more

Zhou,

Leahy,

Grose

et al. 2024

PLoS Negl Trop Dis

View full text Add to dashboard Cite

Background Congenital toxoplasmosis is a treatable, preventable disease, but untreated causes death, prematurity, loss of sight, cognition and motor function, and substantial costs worldwide. Objectives We asked whether high performance of an Immunochromatographic-test (ICT) could enable accurate, rapid diagnosis/treatment, establishing new, improved care-paradigms at point-of-care and clinical laboratory. Methods Data were obtained in 12 studies/analyses addressing: 1-feasibility/efficacy; 2-false-positives; 3-acceptability; 4-pink/black-line/all studies; 5-time/cost; 6-Quick-Information/Limit-of-detection; 7, 8-acute;-chronic; 9-epidemiology; 10-ADBio; 11,12-Commentary/Cases/Chronology. Findings ICT was compared with gold-standard or predicate-tests. Overall, ICT performance for 1093 blood/4967 sera was 99.2%/97.5% sensitive and 99.0%/99.7% specific. However, in clinical trial, FDA-cleared-predicate tests initially caused practical, costly problems due to false-positive-IgM results. For 58 persons, 3/43 seronegative and 2/15 chronically infected persons had false positive IgM predicate tests. This caused substantial anxiety, concerns, and required costly, delayed confirmation in reference centers. Absence of false positive ICT results contributes to solutions: Lyon and Paris France and USA Reference laboratories frequently receive sera with erroneously positive local laboratory IgM results impeding patient care. Therefore, thirty-two such sera referred to Lyon’s Reference laboratory were ICT-tested. We collated these with other earlier/ongoing results: 132 of 137 USA or French persons had false-positive local laboratory IgM results identified correctly as negative by ICT. Five false positive ICT results in Tunisia and Marseille, France, emphasize need to confirm positive ICT results with Sabin-Feldman-Dye-test or western blot. Separate studies demonstrated high performance in detecting acute infections, meeting FDA, CLIA, WHO REASSURED, CEMark criteria and patient and physician satisfaction with monthly-gestational-ICT-screening. Conclusions/significance This novel paradigm using ICT identifies likely false positives or raises suspicion that a result is truly positive, rapidly needing prompt follow up and treatment. Thus, ICT enables well-accepted gestational screening programs that facilitate rapid treatment saving lives, sight, cognition and motor function. This reduces anxiety, delays, work, and cost at point-of-care and clinical laboratories. Trial registration NCT04474132, https://clinicaltrials.gov/study/NCT04474132 ClinicalTrials.gov

show abstract

Section: Discussion (With S1 Commentary )mentioning

confidence: 99%

Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more

Zhou,

Leahy,

Grose

et al. 2024

PLoS Negl Trop Dis

View full text Add to dashboard Cite

show abstract

“…Thanks to this immune response, while deaths related to T. gondii infection occurred in unvaccinated animals, all of the vaccinated animals have survived. Recently, a less invasive homologous vaccination protocol was established, consisting of two nasal administrations at one-month intervals, followed by a nasal boost at 6 months [ 79 ]. A specific, memory T-cell immunity was observed after two administrations in all the squirrel monkeys thus treated, and this immunity lasted for at least 6 months, suggesting that this immunization schedule is sufficient to induce a protective immune response.…”

Section: Lipidated Cationic Maltodextrin Nps For Antigen Deliverymentioning

confidence: 99%

Maltodextrin-Nanoparticles as a Delivery System for Nasal Vaccines: A Review Article

Fasquelle,

Scuotto,

Howsam

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Nanoparticles are increasingly being studied as antigen delivery systems for immunization with nasal vaccines. The addition of adjuvants is still generally required in many nanoparticle formulations, which can induce potential side effects owing to mucosal reactogenicity. In contrast, maltodextrin nanoparticles do not require additional immunomodulators, and have been shown to be efficient vaccine delivery systems. In this review, the development of maltodextrin nanoparticles is presented, specifically their physico-chemical properties, their ability to load antigens and deliver them into airway mucosal cells, and the extent to which they trigger protective immune responses against bacterial, viral, and parasitic infections. We demonstrate that the addition of lipids to maltodextrin nanoparticles increases their potency as a vaccine delivery system for nasal administration.

show abstract

Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model

Abdel-Wahab,

Shafey,

Selim

et al. 2024

Parasitol Res

View full text Add to dashboard Cite

Despite being the initial choice for treating toxoplasmosis, sulfadiazine and pyrimethamine have limited effectiveness in eliminating the infection and were linked to a variety of adverse effects. Therefore, the search for new effective therapeutic strategies against toxoplasmosis is still required. The current work is the first research to assess the efficacy of spiramycin-loaded maltodextrin nanoparticles (SPM-loaded MNPs) as a novel alternative drug therapy against toxoplasmosis in a murine model. Fifty laboratory-bred Swiss albino mice were divided into five groups: normal control group (GI, n = 10), positive control group (GII, n = 10), orally treated with spiramycin (SPM) alone (GIII, n = 10), intranasal treated with SPM-loaded MNPs (GIV, n = 10), and orally treated with SPM-loaded MNPs (GV, n = 10). Cysts of Toxoplasma gondii ME-49 strain were used to infect the mice. Tested drugs were administered 2 months after the infection. Drug efficacy was assessed by counting brain cysts, histopathological examination, and measures of serum CD19 by flow cytometer. The orally treated group with SPM-loaded MNPs (GV) showed a marked reduction of brain cyst count (88.7%), histopathological improvement changes, and an increasing mean level of CD19 (80.2%) with significant differences. SPM-loaded MNPs showed potent therapeutic effects against chronic toxoplasmosis. Further research should be conducted to assess it in the treatment of human toxoplasmosis, especially during pregnancy. Graphical Abstract

show abstract

Nasal vaccination of six squirrel monkeys (Saimiri sciureus): Improved immunization protocol against Toxoplasma gondii with a nanoparticle-born vaccine

Cited by 3 publications

References 20 publications

Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more

Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more

Maltodextrin-Nanoparticles as a Delivery System for Nasal Vaccines: A Review Article

Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model

Contact Info

Product

Resources

About